JP2022546539A5 - - Google Patents

Info

Publication number
JP2022546539A5
JP2022546539A5 JP2022514014A JP2022514014A JP2022546539A5 JP 2022546539 A5 JP2022546539 A5 JP 2022546539A5 JP 2022514014 A JP2022514014 A JP 2022514014A JP 2022514014 A JP2022514014 A JP 2022514014A JP 2022546539 A5 JP2022546539 A5 JP 2022546539A5
Authority
JP
Japan
Prior art keywords
myxv
myxoma virus
activity
protein
reduce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022514014A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546539A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/049061 external-priority patent/WO2021046125A1/en
Publication of JP2022546539A publication Critical patent/JP2022546539A/ja
Publication of JP2022546539A5 publication Critical patent/JP2022546539A5/ja
Pending legal-status Critical Current

Links

JP2022514014A 2019-09-02 2020-09-02 粘液腫ウイルスを用いて癌を治療するための新しい腫瘍崩壊ウイルスプラットフォーム Pending JP2022546539A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962894925P 2019-09-02 2019-09-02
US62/894,925 2019-09-02
US201962944233P 2019-12-05 2019-12-05
US62/944,233 2019-12-05
PCT/US2020/049061 WO2021046125A1 (en) 2019-09-02 2020-09-02 A new oncolytic virus platform to treat cancers with myxoma virus

Publications (2)

Publication Number Publication Date
JP2022546539A JP2022546539A (ja) 2022-11-04
JP2022546539A5 true JP2022546539A5 (cg-RX-API-DMAC7.html) 2023-09-08

Family

ID=74681244

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022514014A Pending JP2022546539A (ja) 2019-09-02 2020-09-02 粘液腫ウイルスを用いて癌を治療するための新しい腫瘍崩壊ウイルスプラットフォーム

Country Status (11)

Country Link
US (3) US11117934B2 (cg-RX-API-DMAC7.html)
EP (1) EP4025228A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022546539A (cg-RX-API-DMAC7.html)
KR (1) KR20220112241A (cg-RX-API-DMAC7.html)
CN (1) CN114615988A (cg-RX-API-DMAC7.html)
AU (1) AU2020342510A1 (cg-RX-API-DMAC7.html)
CA (1) CA3152779A1 (cg-RX-API-DMAC7.html)
IL (1) IL291009A (cg-RX-API-DMAC7.html)
MX (1) MX2022002547A (cg-RX-API-DMAC7.html)
TW (1) TW202122411A (cg-RX-API-DMAC7.html)
WO (1) WO2021046125A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202100305SA (en) 2018-07-13 2021-02-25 Univ Arizona State Methods of treating cancer with tnf expressing myxoma virus
CA3112788A1 (en) * 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer
EP3946373A4 (en) * 2019-03-28 2023-01-11 Arizona Board of Regents, a Body Corporate of the State of Arizona, acting for and on behalf of Arizona State University FAST-PP14-EXPRESSING ONCOLYTIC MYXOMAVIRUS FOR TREATMENT OF BLOOD CANCER
CN114615988A (zh) 2019-09-02 2022-06-10 亚利桑那州立大学董事会 用黏液瘤病毒治疗癌症的新型溶瘤病毒平台
WO2022067038A1 (en) * 2020-09-25 2022-03-31 President And Fellows Of Harvard College Immunotherapeutic virus for the treatment of cancer
JP2024508920A (ja) * 2021-03-01 2024-02-28 オンコミクス セラピューティクス,インク. 多武装の粘液腫ウイルス

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2153284B1 (es) * 1998-06-10 2001-09-01 Fundacion Para El Estudio Y De Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos.
KR100747646B1 (ko) 2005-02-25 2007-08-08 연세대학교 산학협력단 데코린 유전자를 포함하는 유전자 전달 시스템 및 이를 포함하는 약제학적 항종양 조성물
WO2007143545A2 (en) * 2006-06-01 2007-12-13 Robarts Research Institute Tnf signaling in myxoma virus treatments
US8765462B2 (en) 2007-05-04 2014-07-01 University Health Network IL-12 immunotherapy for cancer
FR2946536B1 (fr) * 2009-06-11 2011-07-29 Agronomique Inst Nat Rech Utilisation d'une souche attenuee de myxoma virus comme oncolytique
WO2011156273A1 (en) * 2010-06-06 2011-12-15 Mount Sinai School Of Medicine Recombinant rna viruses and uses thereof
EP2697368B1 (en) * 2011-04-15 2019-06-05 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
EP2717887B1 (en) 2011-06-09 2017-12-27 University of Florida Research Foundation, Inc. Methods for treating or preventing graft versus host disease
ES2895977T3 (es) 2013-11-28 2022-02-23 Bavarian Nordic As Composiciones y métodos de inducción de una respuesta inmunitaria mejorada usando vectores de poxvirus
KR20160140075A (ko) 2015-05-29 2016-12-07 코오롱생명과학 주식회사 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터
AU2016313969B2 (en) * 2015-06-19 2021-12-23 Sillajen, Inc. Compositions and methods for viral embolization
WO2017123675A1 (en) 2016-01-11 2017-07-20 Synlogic, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
CN110050062A (zh) * 2016-08-09 2019-07-23 阿尔莫哈纳德·阿尔卡亚尔 表达il12的溶瘤弹状病毒
WO2018156106A1 (en) 2017-02-22 2018-08-30 Ding Enyu An mrna cancer vaccine encoding human gm-csf fused to multiple tandem epitopes
SG11202100305SA (en) 2018-07-13 2021-02-25 Univ Arizona State Methods of treating cancer with tnf expressing myxoma virus
WO2020033510A1 (en) 2018-08-08 2020-02-13 Arizona Board Of Regents On Behalf Of Arizona State University Method for improved poxvirus yields
BR112021002639A2 (pt) 2018-08-16 2021-05-11 Musc Foundation For Research Development vírus recombinantes do mixoma e usos dos mesmos
CA3112788A1 (en) 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer
EP3946373A4 (en) 2019-03-28 2023-01-11 Arizona Board of Regents, a Body Corporate of the State of Arizona, acting for and on behalf of Arizona State University FAST-PP14-EXPRESSING ONCOLYTIC MYXOMAVIRUS FOR TREATMENT OF BLOOD CANCER
CN114615988A (zh) 2019-09-02 2022-06-10 亚利桑那州立大学董事会 用黏液瘤病毒治疗癌症的新型溶瘤病毒平台
CA3152787A1 (en) 2019-09-02 2021-03-11 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for improving oncolytic virus infection for nonpermissive cancers
JP2024508920A (ja) 2021-03-01 2024-02-28 オンコミクス セラピューティクス,インク. 多武装の粘液腫ウイルス

Similar Documents

Publication Publication Date Title
JP2022543009A5 (cg-RX-API-DMAC7.html)
JP2024026218A5 (cg-RX-API-DMAC7.html)
JP2023113681A5 (cg-RX-API-DMAC7.html)
JP2018100276A5 (cg-RX-API-DMAC7.html)
JP2006516528A5 (cg-RX-API-DMAC7.html)
JP2020532288A5 (cg-RX-API-DMAC7.html)
MX2010009563A (es) Compuestos quimicos con accion antiviral contra virus de dengue y otros flavivirus.
JP2018184433A5 (cg-RX-API-DMAC7.html)
JP2023153863A5 (cg-RX-API-DMAC7.html)
JP2014096359A5 (ja) 電極材料
JP2022540353A5 (cg-RX-API-DMAC7.html)
MX2019010143A (es) Bifidobacterium longum capaz de modular beneficiosamente la respuesta inmune contra una infeccion respiratoria por virus.
JP2022538215A5 (cg-RX-API-DMAC7.html)
JP2018117620A5 (cg-RX-API-DMAC7.html)
JP2013514797A5 (cg-RX-API-DMAC7.html)
JP2023139025A5 (cg-RX-API-DMAC7.html)
JP2018504468A5 (cg-RX-API-DMAC7.html)
JP2018037906A5 (cg-RX-API-DMAC7.html)
WO2015058772A3 (en) Novel hcv culture systems and direct-acting antiviral sensitivity
JP2024038101A5 (cg-RX-API-DMAC7.html)
JP2023508938A5 (cg-RX-API-DMAC7.html)
JP2020099679A5 (cg-RX-API-DMAC7.html)
CN111247131A (zh) 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物
JP2021185485A5 (cg-RX-API-DMAC7.html)
JP2013506570A5 (cg-RX-API-DMAC7.html)